U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07412015) titled 'Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets' on Feb. 03.
Brief Summary: This is a pilot bioequivalence study. It is a randomized, open-label, single-dose, crossover study. The primary objective of this study is to preliminarily evaluate the pharmacokinetic parameters and their variability of the test formulation versus the reference formulation following a single oral dose under fed conditions.
Study Start Date: May 27, 2026
Study Type: INTERVENTIONAL
Condition:
T2DM (Type 2 Diabetes Mellitus)
Intervention:
DRUG: treatment T (dose 1)
Chiglitazar/Metformin extended-release fixed dose combinatio...